sábado, 28 de diciembre de 2013

Network Formed to Discover New Cancer OncoArraySusceptibility Variants

archive.constantcontact.com/fs170/1109148816547/archive/1115953717099.html


Network Formed to Discover New Cancer OncoArraySusceptibility Variants
OncoArray Network Accepting New Members
The OncoArray Network encompasses a group of disease-based consortia interested in gaining new insights into the genetic architecture and mechanisms underlying breast, ovarian, prostate, colorectal, and lung cancers.  

To pursue this goal, they have partnered with Illumina in designing a new chip, the OncoArray, which includes approximately 570,000 single nucleotide polymorphism markers (SNPs); a backbone of approximately 260,000 SNPs providing genome-wide coverage of most common variants; fine-mapping markers for loci of interest identified for breast, ovarian, prostate, colorectal, lung, and other cancers; fine mapping of known susceptibility regions; and loci of interest to multiple cancer types (including loci associated with cancer- related phenotypes, drug metabolism, and radiation response).  

Additionally, SNPs relating to quantitative phenotypes such as body mass index (BMI), height, and breast density that correlate with common cancer risks are also included. The OncoArray Network will process more than 400,000 samples of cancer cases and controls. Because of its high-density genotyping and fine mapping, this project offers an unprecedented opportunity to determine causal variants in known loci and to identify new and rarer variants.

The OncoArray Network welcomes additional members, including investigators studying other diseases. Members can gain access to the SNP-limited annotation list and must agree to abide by the Network's internal data-sharing policies and publication guidelines.View the membership application form here.
The OncoArray Network is funded in part by grants from the National Cancer Institute (NCI), Genome Canada, Cancer U.K., the European Union; and others.


About Us 
Funding Opportunity
AnnouncementsFundingAnnouncements
RFA-CA-13-015
Cancer Detection, Diagnosis, and Treatment Technologies for Global Health (UH2/UH3)
Application due date: January 6, 2014
Expires: January 7, 2014

NCI Provocative Questions RFAs
Application due dates: January 15, 2014; June 20, 2014
Expires: June 21, 2014

RFA-CA-13-010
Sub-Saharan African Collaborative HIV and Cancer Consortia (U54)
Application due date:  January 17, 2014
Expires: January 18, 2014
  
RFA-HG-13-013
Interpreting Variation in Human Non-Coding Genomic Regions Using Computational Approaches and Experimental Assessment (R01)
Application due dates: January 21, 2014; January 21, 2015
Expires: January 22, 2015

PAR-13-382
Analysis of Genome-Wide Gene-Environment (GxE) Interactions (R21)
Application due date:  February 14, 2014
Expires: February 15, 2014

PA-14-003
Collaborative Activities to Promote Metabolomics Research (Admin. Supp.)
Application due date: February 14, 2014
Expires: February 15, 2014

PAR-13-375
Nutrigenetics and Nutrigenomics Approaches for Nutrition Research (R01)
Application due dates: March 20, 2014; March 19, 2015; March 22, 2016
Expires: March 23, 2016

PA-13-377
PA-13-378
Research on Malignancies in the Context of HIV/AIDS (R01, R21)
Application due dates: Standard AIDS dates apply
Expires: September 8, 2016 
Grants Policy AnnouncementsGrantsmanshipAnnouncements
PAR-14-007
NCI Small Grants Program for Cancer Research (NCI Omnibus R03) was released November 21, 2013, Principal Investigators should note changes to application receipt dates.

NOT-OD-14-028
Change in the NIH Continuous Submission Policy
Job OpportunitiesJobOpportunity

Program Director, Clinical and Translational Epidemiology Branch, EGRP 

Program Director, Host Susceptibility Factors Branch, EGRP

Cancer Research Training Award Fellow, Associate Coordinator for Cancer Epidemiology Cohorts and Consortia, EGRP

Chief, Laboratory of Translational Genomics, DCEG
Upcoming Seminars & WorkshopsEvents

NCI-NIBIB Point of Care Technologies for Cancer Conference
January 8-10, 2014 in Bethesda, MD

7th Biennial Cancer Survivorship Research Conference: Advancing Survivorship through Multilevel Collaborations
Abstract Submission Deadline: January 22, 2014, 11:59 p.m.

Evaluating Genomic Evidence for Medical Decision-Making: A Workshop
February 3, 2014 in Washington, DC

Complex Systems, Health Disparities & Population Health: Building Bridges
February 24-25, 2014 in Bethesda, MD

HIV Drug Resistance Program Conference: Host Factors and Cofactors in HIV Infection
February 25, 2014 (rescheduled from October 16, 2013 due to government shutdown) in Frederick, MD
Blog PostBlogPosts
 
About EGRPAboutEGRP
The Epidemiology and Genomics Research Program (EGRP), in theDivision of Cancer Control and Population Sciences (DCCPS)funds research in human populations to understand the causes of cancer and related outcomes.

The Program fosters interdisciplinary collaborations, as well as the development and use of resources and technologies to advance cancer research and translation of this research, which serve as the basis for clinical and public health interventions. 
Send Us Your IdeasSendUsYourIdeas
EGRP encourages readers tosubmit items of interest to Cancer Epidemiology Matters E-News. EGRP reserves the right to decide whether or not materials are appropriate for inclusion. 
Contact UsContactUs
Epidemiology and Genomics Research Program
Division of Cancer Control and Population Sciences
National Cancer Institute
9609 Medical Center Drive
4 East, MSC 9763
Bethesda, MD  20892
(240) 276-6730
e-mailnciepimatters@mail.nih.gov
website: epi.grants.cancer.gov
blog: blog-epi.grants.cancer.gov
Twitter: twitter.com/NCIEpi

For UPS, FedEx, and courier services, please use:
Rockville, MD  20850

No hay comentarios:

Publicar un comentario